Between 1 June 2026 and 7 June 2026 the tracker indexed 21 new peer-reviewed studies and 10 clinical-trial updates across 8 post-viral and post-infectious conditions.
By the numbers
21new studies this issue
10trial updates this issue
544studies currently in the feeds
620clinical trials tracked
546biomarkers catalogued
Studies tracked = entries across the 8 condition feeds (each feed keeps a rolling window of recent PubMed results); trials tracked = ClinicalTrials.gov records in the current trial snapshot (last run 2026-06-26); biomarkers catalogued = marker entries across all OSMF biomarker atlases.
New studies by condition
ME/CFS 8 new
Full feed: ME/CFS research tracker
Children, adolescents, and young adults (CYP) with postacute infection and vaccination syndromes (PAIVS), and/or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), experience profound loss in activity and participation. We introduce and psychometrically validate two new brief, age-adapted, and domain-specific questionnaires for clinical use assessing activity and participation in this vulnerable patient...
Hyperbaric oxygen therapy (HBOT) has been proposed as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), but evidence remains limited. This study evaluated its clinical effectiveness and feasibility, as well as associated functional brain changes.
No abstract available.
No abstract available.
Many of those affected by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have significant care needs. However, post-exertional malaise, the defining feature of ME/CFS, means that even minor physical, orthostatic, cognitive, or sensory stressors can trigger a disproportionate worsening of health status, condition and symptoms.
A patient in her late 30s developed severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following an Epstein-Barr virus infection. No distinct autoimmune or autoinflammatory disorder could be identified as the underlying cause of her symptoms, as the observed constellation of cytokine elevations (IL-2, IL-6, and IFN-γ) was not consistent with any known or established disease entity.
Inflammation-driven fatigue is a clinically significant feature of several chronic inflammatory conditions, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), post-COVID condition, autoimmune disease, and cancer-related fatigue. Across these conditions, partially overlapping disturbances in immune regulation, cellular metabolism, and neuroimmune signaling may contribute to persistent fatigue...
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating condition characterized by persistent fatigue, impaired functioning, and substantial societal burden. Although cognitive behavioral therapy (CBT) is commonly used for CFS/ME, the effective components and delivery formats remain unclear.
Post-Acute COVID-19 Vaccination Syndrome (PACVS) 1 new
Full feed: PACVS research tracker
COVID-19 continues to pose a burden in children under 12 years of age during the Omicron era (November 2021 - December 2025). Following Omicron's emergence, SARS-CoV-2 seroprevalence increased rapidly, with most children infected by ages 2-4 years.
Postural Orthostatic Tachycardia Syndrome (POTS) 9 new
Full feed: POTS research tracker
Postural orthostatic tachycardia syndrome (POTS) as conventionally defined is a chronic condition (typically > 3 months duration) incorporating reproducible symptoms of orthostatic intolerance (including dizziness/lightheadedness, and near-syncope) in the absence of orthostatic hypotension (ie, absence of a sustained systolic blood pressure drop > 20mmHg with upright posture). More recently, however, the :landscape...
No abstract available.
Autonomic dysfunction, characterized by orthostatic intolerance and presyncope, is understudied in youth. Mental health comorbidities are commonly reported and sometimes blamed for the onset of autonomic dysfunction; however, no studies have yet examined this relationship.
Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) is characterized by persistent orthostatic tachycardia and systemic symptoms following SARS-CoV-2 infection. Many features of LCPOTS suggest ongoing immune activation, but the mechanisms driving this response remain unclear.
No abstract available.
No abstract available.
hypermobile spectrum disorders (HSD) and Ehlers-Danlos syndromes (EDS) are connective tissue disorders often associated with systemic manifestations such as mast cell activation syndrome (MCAS), postural orthostatic tachycardia syndrome (POTS), irritable bowel syndrome (IBS), and autoimmune conditions, including spondyloarthritis (SpA). The overlap of these conditions complicates diagnosis and treatment.
No abstract available.
Pediatric postural orthostatic tachycardia syndrome is one of the main haemodynamic types of neurally mediated syncope and is commonly seen in school-aged children. Heart rate and blood pressure are important physiological indicators in the human cardiovascular system.
Other post-viral and post-infectious syndromes 2 new
Full feed: Other post-viral research tracker
Guillain-Barré syndrome (GBS) is a post-infectious autoimmune disorder of the peripheral nerves. While human parvovirus B19 (B19V) is a recognized rare trigger, its diagnosis can be challenging without advanced molecular techniques.
Mycoplasma pneumoniae is a well-recognized respiratory pathogen increasingly associated with diverse neurological manifestations beyond pulmonary disease involvement. To evaluate movement disorders and cerebellar syndromes linked to Mycoplasma pneumoniae, focusing on clinical relevance, diagnosis, and management challenges.
No new studies this window for: Long COVID, Lyme / PTLDS, MCAS.
Trial activity
ClinicalTrials.gov records whose registry entry was last updated between 1 June 2026 and 7 June 2026. A registry update can be anything from a status change to an edited contact field; status shown is as of the tracker snapshot.
| NCT | Trial | Status | Phase | Agents | Updated |
|---|
| NCT06614309 | Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog Long COVID | Recruiting | Not applicable | Acute Progressive Carbon Dioxide, Acute Intermittent Hypoxia, Training: Progressive Carbon Dioxide Ramping | 2026-06-05 |
| NCT07627815 | Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Long COVID | Recruiting | Phase 2 | Paragon Novel Metabolic Regulator, Dietary And Lifestyle Recommendations | 2026-06-04 |
| NCT07621588 | Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID Long COVID | Not Yet Recruiting | Not applicable | Diaphragmatic Electrostimulation Using Kots Currents, Diaphragmatic Breathing Exercises | 2026-06-04 |
| NCT06560554 | Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID Long COVID | Enrolling By Invitation | Not applicable | Fermented Foods | 2026-06-03 |
| NCT06404112 | RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) Long COVID | Completed | Phase 2 | Melatonin, Tailored Lighting (Tl) Active | 2026-06-03 |
| NCT06404099 | RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) Long COVID | Completed | Phase 2 | Modafinil, Solriamfetol | 2026-06-03 |
| NCT06305793 | RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) Long COVID | Active Not Recruiting | Phase 2 | IVIG (Intravenous Immunoglobulin), Coordinated Care | 2026-06-03 |
| NCT07621068 | Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS) ME/CFS | Not Yet Recruiting | Not applicable | Hyperbaric Oxygen Therapy (HBOT) | 2026-06-02 |
| NCT03807973 | Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. ME/CFS | Suspended | Phase 1 | [Zr-89]Oxine-Labeled Leukocytes Pet/Mri | 2026-06-02 |
| NCT03759522 | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. ME/CFS | Recruiting | Phase 1 | Dpa-714 Pet/Mri | 2026-06-02 |
Browse all tracked trials: clinical trials tracker.
Cite this issue
Open Source Medicine Foundation. Post-viral research digest, week 23 2026: 21 new studies. Published 7 June 2026. https://research.opensourcemed.info/digest/2026-W23.html
Issues are regenerated from the live tracker data within their week and frozen afterwards; the snapshot behind this page is at data/2026-W23.json.
Disclaimer. This digest is an automated, unreviewed listing of newly indexed PubMed records and ClinicalTrials.gov registry updates compiled by the Open Source Medicine Foundation. Inclusion is not endorsement; abstracts are excerpted verbatim from PubMed and may contain errors. It is not medical advice. Discuss any treatment decision with a qualified clinician.